Clinical Data to be Presented at ESMO and WCLC
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your HCM notes
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer
Hong Kong, Shanghai & Florham Park, NJ - Monday, September 9, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer ("WCLC24") in San Diego, USA, and the European Society for Medical Oncology ("ESMO") Congress 2024, taking place in Barcelona, Spain.
Results from the FLOWERS study, a prospective, two-arm, randomized, multicenter Phase II clinical trial of osimertinib with or without savolitinib as first-line treatment in EGFRm, MET-aberrant advanced non-small cell lung cancer ("NSCLC") patients, will be presented at WCLC24. As of May 28, 2024, the median follow-up was 8.2 months. Patients treated with osimertinib plus savolitinib (Cohort 2, N=21) showed deeper and more durable response over osimertinib monotherapy (Cohort 1, N=23) along the study follow-up. The confirmed objective response rate (ORR) in Cohort 1 and Cohort 2 were 60.9% and 90.5%, respectively, with disease control rate (DCR) of 87% and 95.2%, respectively. Immature progression-free survival ("PFS") data also showed a positive trend in favor of the combination therapy, with median PFS of 9.3 months and 19.6 months in the cohort 1 and cohort 2 with maturity of 34.8% and 23.8%, respectively. Safety profiles of osimertinib monotherapy and osimertinib plus savolitinib were as expected, tolerable and manageable.
| Abstract title | Presenter / Lead author | Presentation details |
| WCLC24 - INVESTIGATOR-INITIATED STUDIES | ||
| Osimertinib with or without savolitinib as 1L in de novo MET aberrant, EGFRm advanced NSCLC (CTONG 2008): A Phase II trial | Jin j i Yang , Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital , Southern Medical University, Guangzhou, China | PL04.10 Plenary Session PL04 Presidential Symposium 2, Plenary Hall Monday, September 9, 2024 at 8:30 AM PDT |
| Study of Surufatinib Combined with Low Dose Topotecan in Second or Third-Line Multiple Distant Organ Metastatic ES-SCLC | Yingying Du, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Hesheng Qian, Fuyang Cancer Hospital, Fuyang, China | EP.13A.04A ePoster Saturday, September 7, 2024 |
| Surufatinib Plus Docetaxel in Patients with Relapsed Advanced Driver-Negative Non-Squamous NSCLC: A Phase Ib/II Study | Qitao Yu, Wei Jiang, Guangxi Medical University Cancer Hospital, Nanning, China | P3.12C.08 Poster Monday, September 9, 2024 at 8:30 AM PDT |
Further analysis of fruquintinib's FRESCO-2 study in metastatic colorectal cancer and FRUTIGA study in gastric cancer, a biomarker study of savolitinib in gastric cancer as well as investigator-initiated studies of fruquintinib and surufatinib will be presented at the ESMO Congress 2024. Details of the presentations are as follows:
| Abstract title | Presenter / Lead author | Presentation details |
| ESMO 2024 - SPONSORED STUDIES | ||
| Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer with and without liver metastasis: A subgroup analysis of the phase 3 FRESCO-2 trial | Rocio Garcia-Carbonero , Hospital Universitario 12 de Octubre, lmas12, UCM, Madrid, Spain | 520P Poster Session - Colorectal cancer Monday, 16 September 2024 |
| Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age | Maria Elena Elez Fernandez , Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain | 526P Poster Session - Colorectal cancer Monday, 16 September 2024 |
| Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): subgroup analysis from FRUTIGA study | Lin Shen , Peking University Cancer Hospital & Institute, Beijing, China | 1410P Poster Session - Oesophagogastric cancer Monday, 16 September 2024 |
| Impact of subsequent anti-tumor therapies in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma receiving fruquintinib (F) plus paclitaxel (PTX) or placebo plus PTX in FRUTIGA study | Rui h ua Xu , Sun Yat-sen University Cancer Center, Guangzhou, China | 1434P Poster Session - Oesophagogastric cancer Monday, 16 September 2024 |
| Association between Fruquintinib-induced Hypertension and Clinical Outcomes from FRUTIGA, a Phase 3 Study of Fruquintinib plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | Shukui Qin , Chinese People's Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China | 1443P Poster Session - Oesophagogastric cancer Monday, 16 September 2024 |
| Analysis of MET gene alterations in cfDNA samples from a phase II study of savolitinib in patients (pts) with MET-amplified gastroesophageal junction adenocarcinomas or gastric cancer (GEJ/GC) | Zhi Peng , Peking University Cancer Hospital & Institute, Beijing, China | 14 61 P Poster Session - Oesophagogastric cancer Monday, 16 September 2024 |
| ESMO 2024 - INVESTIGATOR-INITIATED STUDIES | ||
| A phase II clinical study of fruquintinib (Fru) combined with toripalimab (Tor) and short-course radiotherapy (SCRT) as neoadjuvant therapy for locally advanced rectal cancer (LARC) | Zhiping Li, Ye Chen , West China Hospital of Sichuan University, Chengdu, China | 570P Poster Session - Colorectal cancer Monday, 16 September 2024 |
| Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE) | Zhen Zhang, Yajie Chen, Fudan University Shanghai Cancer Center, Shanghai, China | 537P Poster Session - Colorectal cancer Monday, 16 September 2024 |
| Fruquintinib combined with sintilimab and chemotherapy as the first-line treatment in advanced naïve EGFR- and ALK-negative non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results | Yongqian Shu , Pei M a, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, China | 1329P Poster Session - NSCLC, metastatic Saturday, 14 September 2024 |
| Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced G/GEJ cancer: A phase 1b/2 clinical trial (FUNCTION) | Xiaobing Chen, Bei b ei Chen , Henan Cancer Hospital/ Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China | 1475TiP Poster Session - Oesophagogastric cancer Monday, 16 September 2024 |
| Fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study | Xianjun Yu, Miaoyan Wei , Fudan University Shanghai Cancer Center, Shanghai, China | 1529P Poster Session - Pancreatic cancer Monday, 16 September 2024 |
| A phase II study of Fruquintinib in the 1L or 2L treatment of unresectable metastatic soft tissue sarcoma | Zhiguo Luo , Xiaowei Zhang , Fudan University Shanghai Cancer Center, Shanghai, China | 1743P Poster Session - Sarcoma Saturday, 14 September 2024 |
| Surufatinib combined with anti-PD-1/PD-L1 antibody in the second line or monotherapy in third line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study | Fuxiang Zhou , Zhongnan Hospital, Wuhan University, Wuhan, China | 974P Poster Session - Hepatocellular carcinoma (HCC) Monday, 16 September 2024 |
| Updated results of Surufatinib plus transarterial embolization versus surufatinib monotherapy in neuroendocrine tumor with liver metastasis: a prospective, randomized, controlled trial | Dan Cao , West China Hospital, Sichuan University, Chengdu, China | 1155P Poster Session - Neuroendocrine tumours Monday, 16 September 2024 |
| Surufatinib plus toripalimab combined with pemetrexed (A), and platinum (P) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsq-NSCLC): Updated results of a single-center, phase II trial | Li Zhang, Wen f eng Fang , Sun Yat-Sen University Cancer Center, Guangzhou, China | 1345P Poster Session - NSCLC, metastatic Saturday, 14 September 2024 |
| Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: a multi-center, phase II trial | Xiaohui Niu, Yuhong Zhou , Zhongshan Hospital, Fudan University, Shanghai, China | 1740P Poster Session - Sarcoma Saturday, 14 September 2024 |
Medical Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.